• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by G1 Therapeutics Inc.

    4/25/24 4:12:57 PM ET
    $GTHX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GTHX alert in real time by email
    DEFA14A 1 d823314ddefa14a.htm DEFA14A DEFA14A

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

     

     

    Filed by the Registrant ☒     Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐    Preliminary Proxy Statement
    ☐    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☐    Definitive Proxy Statement
    ☒    Definitive Additional Materials
    ☐    Soliciting Material Under §240.14a-12

    G1 Therapeutics, Inc.

    (Name of Registrant as Specified in Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒    No fee required.
    ☐    Fee paid previously with preliminary materials.
    ☐    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     


    LOGO

    Online Go to www.envisionreports.com/GTHX or scan the QR code login details are located in the shaded bar below. Votes submitted electronically must be received by June 12, 2024 at 11:59 P.M., local time. Stockholder Meeting Notice Important Notice Regarding the Availability of Proxy Materials for the G1 Therapeutics, Inc. Stockholder Meeting to be Held on June 13, 2024 Under Securities and Exchange Commission rules, you are receiving this notice that the proxy materials for the annual stockholders’ meeting are available on the Internet. Follow the instructions below to view the materials and vote online or request a copy. The items to be voted on and location of the annual meeting are on the reverse side. Your vote is important! This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The Form 10-K, Notice and Proxy Statement for the year ended December 31, 2023, are available at: www.envisionreports.com/GTHX Easy Online Access View your proxy materials and vote. Step 1: Go to www.envisionreports.com/GTHX. Step 2: Click on Cast Your Vote or Request Materials. Step 3: Follow the instructions on the screen to log in. Step 4: Make your selections as instructed on each screen for your delivery preferences. Step 5: Vote your shares. When you go online, you can also help the environment by consenting to receive electronic delivery of future materials. Obtaining a Copy of the Proxy Materials – If you want to receive a copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. Please make your request as instructed on the reverse side on or before June 1, 2024 to facilitate timely delivery.


    LOGO

    Stockholder Meeting Notice G1 Therapeutics, Inc.’s Annual Meeting of Stockholders will be held on June 13, 2024 at G1 Therapeutics, Inc., 700 Park Offices Drive, Research Triangle Park, NC 27709, at 7:30 a.m. local time. Proposals to be voted on at the meeting are listed below along with the Board of Directors’ recommendations. The Board of Directors recommends a vote FOR all nominees and FOR Proposals 2, 3 and 4. 1. The election of two Class I directors 01—John E. Bailey, Jr. 02—Cynthia L. Flowers 2. An advisory (non-binding) vote to approve executive compensation 3. The ratification of the appointment of PricewaterhouseCoopers LLP as G1 Therapeutics, Inc.’s independent registered public accounting firm for the fiscal year ending December 31, 2024 4. Approval of the amendment and restatement of G1 Therapeutics, Inc.’s Certificate of Incorporation to reflect new Delaware law on provisions regarding officer exculpation PLEASE NOTE – YOU CANNOT VOTE BY RETURNING THIS NOTICE. To vote your shares you must go online or request a paper copy of the proxy materials to receive a proxy card. If you wish to attend and vote at the meeting, please bring this notice with you. Here’s how to order a copy of the proxy materials and select delivery preferences: Current and future delivery requests can be submitted using the options below. If you request an email copy, you will receive an email with a link to the current meeting materials. PLEASE NOTE: You must use the number in the shaded bar on the reverse side when requesting a copy of the proxy materials. Internet – Go to www.envisionreports.com/GTHX. Click Cast Your Vote or Request Materials. Phone – Call us free of charge at 1-866-641-4276. Email – Send an email to [email protected] with “Proxy Materials G1 Therapeutics, Inc.” in the subject line. Include your full name and address, plus the number located in the shaded bar on the reverse side, and state that you want a paper copy of the meeting materials. To facilitate timely delivery, all requests for a paper copy of proxy materials must be received by June 1, 2024.

    Get the next $GTHX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GTHX

    DatePrice TargetRatingAnalyst
    1/30/2023$7.00 → $10.00Underweight → Neutral
    JP Morgan
    1/3/2023$32.00 → $31.00Buy
    Needham
    11/4/2021$20.00 → $19.00Neutral → Underweight
    JP Morgan
    11/4/2021$78.00 → $71.00Buy
    HC Wainwright & Co.
    11/4/2021$41.00 → $24.00Outperform
    Raymond James
    10/15/2021$51.00Buy
    BTIG Research
    9/30/2021$24.00 → $20.00Overweight → Neutral
    JP Morgan
    9/1/2021$57.00 → $56.00Buy
    Roth Capital
    More analyst ratings

    $GTHX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal & People Officer Thomas Monica R. returned 138,151 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - G1 Therapeutics, Inc. (0001560241) (Issuer)

    9/18/24 4:15:18 PM ET
    $GTHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Flowers Cynthia Louise returned 20,000 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - G1 Therapeutics, Inc. (0001560241) (Issuer)

    9/18/24 4:15:17 PM ET
    $GTHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Secor Alicia returned 20,000 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - G1 Therapeutics, Inc. (0001560241) (Issuer)

    9/18/24 4:15:19 PM ET
    $GTHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GTHX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for COSELA

    Submission status for G1 THERAPEUTICS INC's drug COSELA (ORIG-1) with active ingredient TRILACICLIB DIHYDROCHLORIDE has changed to 'Approval' on 02/12/2021. Application Category: NDA, Application Number: 214200, Application Classification: Type 1 - New Molecular Entity

    2/16/21 4:31:16 PM ET
    $GTHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for COSELA

    Submission status for G1 THERAPEUTICS INC's drug COSELA (ORIG-1) with active ingredient TRILACICLIB has changed to 'Approval' on 02/12/2021. Application Category: NDA, Application Number: 214200, Application Classification: Type 1 - New Molecular Entity

    2/16/21 11:21:53 AM ET
    $GTHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    February 12, 2021 - FDA Approves Drug to Reduce Bone Marrow Suppression Caused by Chemotherapy

    For Immediate Release: February 12, 2021 Today, the U.S. Food and Drug Administration approved Cosela (trilaciclib) as the first therapy in its class to reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving certain types of chemotherapy for extensive-stage (when the cancer has spread beyond the lungs) small cell lung cancer. Cosela may help protect bone marrow cells from damage caused by chemotherapy by inhi

    2/12/21 5:24:11 PM ET
    $GTHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GTHX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    G1 Therapeutics upgraded by JP Morgan with a new price target

    JP Morgan upgraded G1 Therapeutics from Underweight to Neutral and set a new price target of $10.00 from $7.00 previously

    1/30/23 7:33:11 AM ET
    $GTHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Needham reiterated coverage on G1 Therapeutics with a new price target

    Needham reiterated coverage of G1 Therapeutics with a rating of Buy and set a new price target of $31.00 from $32.00 previously

    1/3/23 11:04:19 AM ET
    $GTHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    G1 Therapeutics downgraded by JP Morgan with a new price target

    JP Morgan downgraded G1 Therapeutics from Neutral to Underweight and set a new price target of $19.00 from $20.00 previously

    11/4/21 7:46:08 AM ET
    $GTHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GTHX
    SEC Filings

    View All

    SEC Form 15-12G filed by G1 Therapeutics Inc.

    15-12G - G1 Therapeutics, Inc. (0001560241) (Filer)

    9/30/24 7:54:55 AM ET
    $GTHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by G1 Therapeutics Inc.

    S-8 POS - G1 Therapeutics, Inc. (0001560241) (Filer)

    9/18/24 4:14:56 PM ET
    $GTHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by G1 Therapeutics Inc.

    S-8 POS - G1 Therapeutics, Inc. (0001560241) (Filer)

    9/18/24 4:13:56 PM ET
    $GTHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GTHX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Global Cancer Rates Surge as Biotech Innovators Work on New Therapies

    Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Sept. 20, 2024 /PRNewswire/ -- USA News Group – Cancer rates are rising globally, and the outlook is particularly concerning for men. A recent global study projects an 84% increase in cancer cases and a 93% rise in cancer deaths among men by 2050. According to Our World in Data, cancer has overtaken cardiovascular diseases as the leading cause of death in several wealthy nations. Despite warnings from the American Cancer Society, which found that 44% of cancer deaths in U.S. adults are linked to lifestyle factors, troubling trends continue. Another study revealed that even light drinking is associated with an increase in cancer death

    9/20/24 11:08:00 AM ET
    $GTHX
    $HALO
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Pharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender Offer

    - Transaction Will Maximize the Access and Uptake of COSELA® (trilaciclib), the First and Only Proactive Multilineage Myeloprotection Agent - - G1 Stockholders to Receive U.S. $7.15 Per Share in Cash - HOLBAEK, Denmark and RESEARCH TRIANGLE PARK, N.C., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Pharmacosmos A/S, a leader in the development of innovative treatments for patients suffering from iron deficiency and iron deficiency anemia, and G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company focused on delivering next-generation therapies that improve the lives of those affected by cancer, today announced that Pharmacosmos A/S has successfully completed the previously announce

    9/18/24 8:54:59 AM ET
    $GTHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pharmacosmos Group and G1 Therapeutics Announce Expiration of Hart-Scott-Rodino Waiting Period

    HOLBAEK, Denmark and RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Pharmacosmos A/S, a leader in the development of innovative treatments for patients suffering from iron deficiency and iron deficiency anemia, and G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company focused on delivering next-generation therapies that improve the lives of those affected by cancer, today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the "HSR Act") relating to Pharmacosmos' previously announced acquisition of G1 Therapeutics. The expiration of the waiting period occurred at 11:59 p.m. EST on September 4, 2

    9/5/24 6:30:00 AM ET
    $GTHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GTHX
    Financials

    Live finance-specific insights

    View All

    G1 Therapeutics Provides Second Quarter 2024 Financial Results and Operational Highlights

    - Entered into Definitive Merger Agreement to be Acquired by Pharmacosmos; Transaction Expected to Close in Late Third Quarter 2024 - - Achieved $15.8 Million in Net Revenue from Sales of COSELA® (trilaciclib) - - Drove Double Digit Quarter-Over-Quarter Growth in COSELA Vial Volume and Net Revenue - - Reaffirmed 2024 Net COSELA Revenue Guidance of Between $60 and $70 Million - - Due to the Pending Transaction with Pharmacosmos, G1 will Not Host a Conference Call and Webcast to Discuss the Second Quarter Financial Results and Business Update - RESEARCH TRIANGLE PARK, N.C., Aug. 08, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today

    8/8/24 6:30:57 AM ET
    $GTHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pharmacosmos Group to Acquire G1 Therapeutics

    - Business Combination Expected to Provide Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) Optimal Access to G1's COSELA® (trilaciclib), the First and Only Proactive Multilineage Myeloprotection Agent - - Pharmacosmos' Significant Resources and Expertise in Hematology and Supportive Care to Maximize Availability of COSELA for Patients with ES-SCLC - - Transaction Expands and Strengthens Pharmacosmos' Global Commercial Portfolio - - G1's Shareholders to Receive U.S. $7.15 per Share in Cash for a Total Equity Value of Approximately $405 Million - RESEARCH TRIANGLE PARK, N.C. and HOLBAEK, Denmark, Aug. 07, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASD

    8/7/24 6:29:00 AM ET
    $GTHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    G1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024

    RESEARCH TRIANGLE PARK, N.C., July 25, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a financial and corporate update for the second quarter of 2024 on Thursday August 8, 2024, at 8:30 a.m. ET. To register for the event and receive a dial in number and unique PIN to access the live conference call, please follow this link to register online. While not required, it is recommended that you join 10 minutes prior to the start of the event. A live and archived webcast will be available on the Events & Presentations page of the company's website: www.g1therapeutics.com. The webcast will be ar

    7/25/24 11:15:18 AM ET
    $GTHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GTHX
    Leadership Updates

    Live Leadership Updates

    View All

    G1 Therapeutics Announces Appointment of Monica Thomas as General Counsel

    RESEARCH TRIANGLE PARK, N.C., May 22, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced the appointment of Monica Thomas as its General Counsel and Chief Compliance Officer. Mrs. Thomas replaces Stillman Hanson who departed the Company in May 2023. "G1 is in the midst of an important period in our evolution, as we evolve our commercial and clinical capabilities to maximize the future value of COSELA® (trilaciclib) and ensure that all appropriate patients may have access to this important drug," said Jack Bailey, Chief Executive Officer of G1 Therapeutics. "As we do so, it is essential that we maintain our fundamental focus o

    5/22/23 4:45:22 PM ET
    $GTHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    G1 Therapeutics Announces Addition of Norman E. Sharpless to Board of Directors

    RESEARCH TRIANGLE PARK, N.C., July 25, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced the appointment of Norman E. "Ned" Sharpless, M.D., to its Board of Directors. For nearly 30 years, Dr. Sharpless has been committed to the fight against cancer, including serving as one of the scientific founders of G1 in 2008. He is an accomplished oncologist and seasoned public servant who has treated cancer patients, investigated the biologic basis of cancer, and has led academic institutions and government agencies, including most recently serving as Director of the National Cancer Institute (NCI) at the National Institutes of Health

    7/25/22 6:30:43 AM ET
    $GTHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    G1 Therapeutics Announces Addition of Jacks Lee to Board of Directors

    RESEARCH TRIANGLE PARK, N.C., June 28, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced the appointment of Jacks Lee to its Board of Directors. For more than 30 years, Mr. Lee has developed extensive experience in manufacturing and supply chain management in the life sciences industry. Mr. Lee currently serves as Senior Vice President – Manufacturing & Supply of Merck & Co., Inc., a global premier research-intensive biopharmaceutical health care company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies, and animal health products. "G1's Board of Directors comprises ex

    6/28/22 7:30:00 AM ET
    $GTHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GTHX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by G1 Therapeutics Inc.

    SC 13G - G1 Therapeutics, Inc. (0001560241) (Subject)

    8/19/24 7:02:21 PM ET
    $GTHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by G1 Therapeutics Inc. (Amendment)

    SC 13D/A - G1 Therapeutics, Inc. (0001560241) (Subject)

    2/21/24 4:30:39 PM ET
    $GTHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by G1 Therapeutics Inc. (Amendment)

    SC 13G/A - G1 Therapeutics, Inc. (0001560241) (Subject)

    2/9/23 11:19:27 AM ET
    $GTHX
    Biotechnology: Pharmaceutical Preparations
    Health Care